Xin Lang Cai Jing·2026-03-27 06:53Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 yuan per share, with a total market capitalization of 45.91 billion yuan, and a cumulative increase of 6.82% over the past three days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Fund Holdings - Six funds under Galaxy Fund hold a total of 2.8611 million shares of Tiger Med, with a floating profit of approximately 7.27 million yuan based on the stock price increase [2][6]. - The largest holding fund, Galaxy Medical Mixed A, reduced its holdings by 7,600 shares in the fourth quarter, now holding 722,300 shares, which represents 9.44% of the fund's net value [3][7]. - Other funds, such as Galaxy Industry Mixed A and Galaxy Research Selected Mixed A, also reduced their holdings but still maintain significant positions, with floating profits of approximately 175.21 thousand yuan and 163.53 thousand yuan, respectively, over the past three days [4][8].